The mode of binding of four active-site directed inhibitors to human thrombin has been determined by xray crystallographic analysis. The inhibitors studied are benzamidine, PPACK, NAPAP, and MD-805, of which the last three are compounds evolved specifically to inhibit thrombin. Crystal structures were determined in the presence of both the inhibitor and the undecapeptide [des-amino Aspss]hirudin(55-65) which binds distant from the active site. Despite having significantly different chemical structures, NAPAP and MD-805 bind to thrombin in a very similar "inhibitor binding mode" which is not that expected by direct analogy with the binding of substrate. Both inhibitors bind to thrombin in a similar way as to trypsin, but thrombin has an extra loop, the "Tyr-Pro-Pro-Trp loop," not present in trypsin, which gives further binding interactions and is seen to move somewhat to accommodate binding of the different inhibitors. The fact that NAPAP and MD-805 require different stereochemistry for potent inhibition is demonstrated, and its structural basis clarified. The wealth of data on analogs and variants of these lead compounds is shown to be compatible with this inhibitor binding mode.
The serine protease thrombin has received much attention because of its central role in the initiation of blood coagulation. The ability to specifically inhibit thrombin in vivo with small synthetic compounds would be an important step toward the prevention of thrombotic problems, as well as providing a tool for the further investigation of the complicated processes of hemostasis and thrombosis. PPACK,' which binds covalently with kinact = 1.2 X lo7 M-' s-l (1, 2) , and the reversible inhibitors NAPAP with K, = 6.6 nM (racemic form) (3) and MD-805 with Ki = 39 nM (4) are the results of three separate efforts to develop efficient thrombin inhibitors. Their structures are shown in Fig. 1 . Other groups have studied the binding of MD-805 and NAPAP to trypsin as a model system for thrombin (5, 6) . We chose to investigate the binding of these compounds to human thrombin, in order to * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "aduertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
$ To whom correspondence should be addressed. better understand both the tight binding to thrombin and the selective binding to thrombin rather than to trypsin.
Since it has proved difficult to obtain well diffracting crystals of either native thrombin or thrombin inhibited just at the active site (e.g. Ref. 7) , we looked for a different system in which to crystallize thrombin with non-covalent active site-directed inhibitors. We followed a report of Owen et al. (8) where the binding of hirudin COOH-terminal peptides to the "anion-binding exosite" (distant from the active site) had been studied and optimum binding found for the undecapeptide [des-amino Asp55] hirudin(55-65), the "hirudin peptide." It was hoped that this peptide would give thrombin some additional protection against autolysis and favor new crystal forms. This was indeed the case and enabled us to determine the structures described.
The lead thrombin inhibitors NAPAP and MD-805 were found to show a novel mode of binding to thrombin, which we have called "inhibitor-like.'' This is characterized by the packing together of the two hydrophobic inhibitor moieties, interaction of this structure with a double hydrophobic pocket formed with the help of the Tyr-Pro-Pro-Trp loop, and by hydrogen bonding to the backbone of Gly-228 12161, without, however, using the oxyanion hole.
These lead compounds are already highly optimized, but our structural results make it possible to propose modifications which would improve the binding to thrombin.
Alternatively, one can now attempt to suggest chemically different molecules which would occupy the same binding pockets, with the hope that some of these might have pharmacologically interesting profiles.
A recurrent problem in the development of new chemical compounds intended to bind to a particular target macromolecule is to know which of a particular series of compounds show the same, or closely similar, binding modes. This is an absolute prerequisite for the valid analysis of structure-property correlations. Here we are in a position to survey the large amount of published binding data on NAPAP and MD-805 analogs in the light of the experimentally determined structures, and conclude that this data may be satisfactorily explained using only the binding mode observed for NAPAP and MD-805. It proved necessary, however, in some cases, to perform detailed conformational analysis. This indicates the requirement for both a reliable experimental basis and careful modeling in order to come to a proper understanding of structure-property correlations.
EXPERIMENTAL PROCEDURES
Human thrombin was purified according to the method of Fenton et al. (9) . PPACK was purchased from Behring Diagnostics and Dand L-NAPAP, MD-805, and the hirudin COOH-terminal peptide [des-amino-Asp'"Ihirudin(55-65) synthesized in house. For crystallization the inhibited thrombin was brought to a concentration of 10 mg/ml in 10 mM Tris-HC1, pH 8 SerZo6 (195) and His43 (57) (l), the proline and arginine have the naturally occurring L-conformer, and the phenylalanine is the unnatural D-isomer. Both stereoisomers of NAPAP were synthesized and tested for thrombin binding. The D-isomer was found to be more than 1000 times more active than the L-isomer, and was used in this work. As in the original work, (4), MD-805 was synthesized as the active Larginine derivative, with the quinoline stereoisomers unresolved. yleneglycol concentration, salt concentration and mixing ratio of protein and precipitant. We used the heavy atom method to solve the structure of the PPACK ternary complex. All inhibitor and derivative data were measured at room temperature with a "Xentronics" area detector at a crystal to detector distance of 16 cm, on an Elliot GX21 rotating anode x-ray generator operating at 40 kV, 75 mA using a graphite monochromator. Frames were processed with the XDS program (11) and reflections accepted to an outer resolution limit where 50% had intensities of less than three standard deviations. The data statistics and effective resolution are shown in Table I for all data sets referred to below. Further data processing was with the CCP4 program package (Daresbury Laboratory, United Kingdom).
A platinum-tetrachloride derivative was found quite readily, having three sites (the major site is the PPACK NH2 terminus). An iridium hexachloride derivative proved to be very similar but poorly isomorphous and was not used. Other heavy atom derivatives proved difficult to find so we took the approach of doubly iodinating the hirudin peptide on tyrosine 63 before cocrystallization. This gave an extremely isomorphous "di-Iodo" derivative, which was solved by applying single isomorphous replacement phases determined from the platinum derivative to the iodine differences. Two equal iodine sites were found at the correct spacing from each other. The derivatives were refined independently using the centric reflections (Table 11) . B-values and scale factors could not be stably refined and were set by hand. Both derivatives had phasing power (mean heavy atom contribution/residual error) of about 2.0 at low resolution and 1.0 at 3.5-A resolution. Two-derivative phases, without the use of anomalous scattering data, gave an electron density map where P-sheet structure could be easily identified. The correct hand was determined from the twist of the P-sheet. When 100 Cas had been placed in density it was straightforward to correctly orient a trypsin model to provide a start for thrombin model building, using FRODO (12) . The TNT program (13) was used for refinement with the parameters suggested by the authors, the final ratio of structure factor to geometry weights being 4 X 10". Temperature factors were refined using the TNT module BCORREL, which limits the temperature factor difference between bonded atoms. The final root mean square difference in B-values between bonded atoms lies in the range 2.5-2.8. Apart from disordered surface features the B-values vary slowly and smoothly through the structure. Water molecules were added using the program PADDIN, written by ourselves for this purpose, which places atoms in peaks of electron density occurring at positions giving reasonable hydrogen bonding. Their temperature factors were refined, and only the 50 best watgrs were kept for each structure, the maximum B-value being 45 A*. At a late stage of the refinement the PPACK complex was used to solve by molecular replacement two crystal structures of the ternary complex of hirudin with PPACKthrombin? These were both refined to R-factors of 21% at 2.9-and 2.35-A resolution, respectively. The hirudin NH2-terminal domain is in both cases almost totally disordered, and the refined structures are extremely similar to that of the PPACK-thrombin-hirudin peptide complex (root mean square difference in Ca coordinates for B1-B144
and B156-B257 of 0.71 A, better locally) and were most useful for checking details of the structures presented here, confirming in particular, the correct assignment of water molecules. (For the benzamidine complex, water molecules were simply taken from the NA-PAP complex: the resolution of this data is too low to allow reliable determination of the water structure). Inhibitor molecules were constructed using the program MOLOC (14) . The covalent linkages of PPACK to thrombin were given target geometries taken from the results of Navia et al. (15) for an elastase-peptide chlormethylketone complex. Table I11 gives the final refinement statistics. The analysi? of Read (16) gives root mean square coordinate errors of 0.26-0.28 A for all these structures.
RESULTS
The thrombin structure is extremely simi!ar in all four of the inhibitor complexes studied (see Table IV ), and inhibitors and protein are well defined in the crystal with the exception of the first seven amino acids of the A-chain and the last three of the B-chain. Fig. 2 shows the active site region of the thrombin-benzamidine complex with the corresponding region of bovine trypsin superposed.
The following five segments are of interest to the present discussion.
1) (57-6OG) includes the active site histidine 43 (57) and the 10-residue insertion relative to trypsin which gives the thrombin active site its unique character. The TyrPro-Pro-Trp loop 47-50 (60A-D) has well-defined electron density in all cases. The following Asp51 (60E) side chain is disordered, but Lys52 (60F) always has a well-defined side chain which moves slightly in response to inhibitor binding. A d 3 (60G) is the carbohydrate attachment site. It was not possible to model the carbohydrate chain, although some electron density can be seen.
' D. W. Banner and P. Hadvary, manuscript in preparation.
2) Trpg2-Leug6 (96-99) forms a turn of left-handed helix and is 1 residue longer than in trypsin. TrpS2 (96) interacts with Pro4' (SOB), Leug6 (99) is involved in inhibitor binding (see below), and Ar$3 (97) and Glug4 (97A) have disordered side chains which point into solution.
3) Thr177-Arg'80 (172-175) has the sequence Tyr-Pro-GlyAsn in trypsin and Thr-Arg-Ile-Arg in thrombin and presents in thrombin the Ile17' (174) side chain toward the active site. There is consistent electron density for this side chain although the other 3 residues appear somewhat disordered.
4) Ser226-Cys231 (214-220) forms one side of the recognition pocket and is conserved between trypsin and thrombin except for GluZ2' in thrombin which is Ser (217) in trypsin.
5) (189-195) forms the other side of the recognition pocket and is also conserved between thrombin and trypsin except for G1u202 in thrombin which is Gln (192) in trypsin and Alazm in thrombin which is Ser (190) in trypsin. The G1u202 side chain seems to take up more than one conformation, as does the corresponding Gln in trypsin. Ala200 is next to Asp"' (189) which is the acidic residue at the bottom of the recognition pocket which provides the specificity for basic amino acids (17) . The change from serine in trypsin to alanine in thrombin makes little change to the protein structure, but may contribute to thrombin's greater specificity for arginine as opposed to lysine.
The negatively ch!rged hirudin COOH-terminal peptide binds more than 20 A away from the active site serine to a positively charged region of thrombin (not shown). In particular, binding is seen to the segment 68-74 (73-77A) containing arginines 68, 70, and 74 (73, 75, and 77A), and thus the pautolytic sites are protected (see Refs. 1, 9, 18, 19) . The peptide has a largely extended conformation and makes hydrophobic as well as charge-charge interactions with the B-chain of thrombin. In these crystals the peptide also interacts with two neighboring thrombin molecules and is tightly bound in the crystal.
Two thrombin structures have been recently reported the binary complex with PPACK by Bode et al. (1) and the binary complex with hirudin by both Rydel et al. (20) and Griitter et al. (21) . Our structural model seems to be extremely similar to those reported and only the active site region will be shown here in detail. (Surprisingly, our crystal form is the same as that of the binary thrombin-hirudin complex, which may well occur because both Rydel et al. (20) and Griitter et al. (21) used recombinant hirudin which, unlike the native hirudin, is not sulfated on Tyr63, and thus has a COOH-terminal sequence identical to the peptide used in the present work.)
There is a surface loop of thrombin which seems not directly related to the binding of the inhibitors studied here, but which is near to the active site and may play a biological role not yet determined, vis the loop around Trp14' (148) with sequence Glu-Thr-Trp-Thr-Asn-Val-Gly-Lys (the y cleavage site) (not shown). In our crystals this loop extends away from the active
TABLE I11
Refinement statistics for the final structures Values given are for constrained temperature factor refinement including 50 water molecules as described in the text. In parentheses are the corres onding values with an overall temperature-factor and no water molecules.
Benzamidine data is from 6 to 3.16 1, otherwise the outer resolution limit is 3.0 A. rms, root mean square. (1) in PPACK-thrombin, and we do not know how this loop is structured in solution, if at all.
The structure of the PPACK-and benzamidine-thrombin complexes are shown in Fig. 3 for the active site region. The loop Tyr-Pro-Pro-Trp (47-50) (60A-D) creates with TrpZz7 ('2151, Leus6 (991, and Ile17' 1174) a double hydrophobic pocket which we divide into a "D-pocket" (Distal to the active site serine) and a "P-pocket" (Proximal to the active site serine). PPACK binds with the D-Phe in the D-pocket and the Pro in the P-pocket. Benzamidine does not use these binding pockets and so the benzamidine complex can be taken as representative of the relaxed native structure for analysis of the thrombin response to inhibitor binding (Table IV) . For comparison purposes the refined coordinates have been kept in the crystallographic system rather than attempting an optimum superposition of the active site residues. This has revealed that for most of the molecule all the inhibitor complexes have structures identical within experimental error. In the PPACK complex, however, we see that in the region shown in Fig. 3 there are many shifts of about 0.5-0.8 8, relative to the benzamidine complex. These shifts were analyzed by optimizing the superposition of the two molecules. This reveals a relative rigid body rotation of about 1" for most of the molecule with the exception of the Tyr-Pro-Pro-Trp loop and the loop packing against it (on the left in Figs. 2 and  3) , which contains Trpg2 (96). This second loop retains its position in the crystal presumably because of the weak crystal contact in this region (involving Ar$' { 1011, not shown), and it seems to move the rest o f the molecule through the interaction of the catalytic triad residues Asps9 (102) and His43 (57) with PPACK (Figs. 2 and 3) . The Tyr-Pro-Pro-Trp loop very clearly moves so as to accommodate the PPACK proline in the P-pocket, the maximum atomic shift being 1.5 A.
The NAPAP and MD-805 thrombin complexes are compared in Fig. 4 with the difference electron densities to the benzamidine complex shown in Fig. 5 . The piperidine moieties of both inhibitors bind in the P-pocket making a hydrophobic interaction with the active site histidine. The larger hydrophobic groups bind in the D-pocket and pack tightly against the piperidine group in the P-pocket. The SOz groups are exposed to solvent near the position of the PPACK NHz terminus, and two hydrogen bonds are made to the backbone of G1yZz8 (216). The oxyanion hole is not used directly by either inhibitor, but rather there is a water molecule there, hydrogen bonded to a further water in both cases (Fig. 5) . This second water molecule is hydrogen bonded to the N{ of Lys5' (60F) and to the carbonyl group of the para-amidino phenyl alanine of NAPAP or to the carboxylate of MD-805. With PPACK bound there are equivalent water molecules displaced toward Trp50 (60D) by about 1 A due to the substituent on the 07 of SerZo5 (195). MD-805 has a bridging water between the arginine Ne and the inhibitor carboxylate group, and PPACK has an analogous water bridging to its NHz terminus and also to the carboxylate of G1uzoZ (192) . In both cases these serve to fill up the recognition pocket. As they come rather close to benzamidine atoms they have been left out of the diagrams for clarity. For NAPAP there exists an alternative conformer in which the naphthyl ring is rotated 180" about the bond to the sulfur. Small adjustments to the sulfonamide conformation allow the electron density to be fitted quite well. Both alternatives have been refined and give identical refinement statistics. Difference maps for each alternative give a weak indication that some of the other conformation may be present. This may also be the case for NAPAP bound to trypsin as Bode et al. (6) found high temperature factors for the naphthyl ring. We also have no indication as to the preferred conformation or configuration of the quinoline ring of MD-805. The binding of aryl-sulfonyl groups is discussed further below. In contrast to PPACK, neither inhibitor alters the thrombin structure by more than 1 A (Table IV) , although there are rearrangements of 0.5-1.0 A which make clear structural sense in terms of thrombin adapting to the particular inhibitor in question (Fig.  4) . This implies that attempts (e.g. Ref. 6 ) to model thrombin inhibitor binding must allow for some relaxation of the protein structure, in particular the Tyr-Pro-Pro-Trp loop.
DISCUSSION
Binding Pockets for Substrates and Inhibitors-The mode of interaction of serine proteases with their substrates has . been studied in great detail and is well understood, although crystallographic data from enzyme-substrate complexes is not available. Substrate specificity comes first from the S1 site (the recognition pocket), and from the S2, S3, etc. sites on the NH2-terminal side and the Sl', S2', etc. sites on the COOH-terminal side. In proteases of the trypsin family, the S1 site is specific for basic amino acids, trypsin being unselective for lysine or arginine and thrombin having a preference for arginine. Trypsin otherwise has very little substrate specificity, binding the substrate main-chain NH, terminus to the cleavage site via an antiparallel , 8 interaction (with Ser-TrpGly 1214-216)) without havingparticularly specific side chainbinding pockets. This is in stark contrast to, for example, the aspartyl proteases, where the substrate is extended and the enzyme has well-defined side chain-binding pockets on both sides of the catalytic center (22-24) .
Some information on thrombin-substrate interactions is available from nuclear magnetic resonance studies (25-27) on complexes of thrombin with analogs of the fibrinopeptide (the NH2-terminal part which is cleaved off from the natural substrate fibrinogen), which indicate that substrates with the sequence Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg prior to the
FIG. 5. Observed difference electron densities for NAPAP and MD-
805. A , the difference electron density between thrombin-NAPAP and thrombin-benzamidine computed using phases from the refined benzamidine complex and differences of observed amplitudes for all common reflections out to 3.16-A resolution. (The faint structures at lower front and bottom right come from the NH2 and COOH termini of a neighboring molecule in the crystal.) Crosses represent provisional water molecules or isolated atoms generated by the spherical cut-off utilized. B, difference electron density for MD-805 minus benzamidine computed as for A .
B
cleavage site adopt a tertiary structure with the Gly-Val-Arg in an extended conformation and the rest folded to bring the Phe and Leu side chains near to the Val side chain. Docking of such a structure on the PPACK-thrombin structure strongly suggests that the Gly-Val-Arg sequence would make the above mentioned antiparallel / 3 interaction with thrombin, putting the Val side chain in the P-pocket and the Phe side chain in the D-pocket. The P-pocket is similar to an S2 pocket, but the D-pocket (Bode et al. (6) use the term "arylbinding site") confers specificity for either hydrophobic Damino acids (PPACK and analogs) or for folded structures (fibrinopeptide and analogs) and is not strictly an S3 pocket.
The high specificity of thrombin is thus explained principally by the presence of the P-and D-pockets, although interactions at other sites are clearly of importance for large natural substrates.
The as shown schematically in Fig. 6 . NAPAP may also be modeled in a similar way. We have called this "substrate-like" inhibitor binding.
Our results on thrombin binding are similar to those on trypsin binding (5, 6) and show that both NAPAP and MD-805 bind in a way different from substrates. We have called this "inhibitor-like" binding. This is shown schematically in Fig. 7 and is characterized by a close interaction of the two hydrophobic groups and the absence of a direct interaction with the oxyanion hole. The two inhibitors make use of almost exactly the same contacts with the enzyme to give their tight binding, although it is not immediately apparent from their chemical formulas that this is possible, as NAPAP has a glycine "spacer" which is absent in MD-805 and the basic amino acid has the opposite stereochemistry (see Fig. 1 ). The observed structures (Fig. 4) enable these apparent contradictions to be readily understood. We see that both compounds make the "P3" anti-parallel p hydrogen bonds to G1yZz8 (216), as does the D-Phe of PPACK, but, remarkably, in MD-805 it is the arginine that does this and in NAPAP it is the glycine. Thus, although both compounds were developed as substrate analogs, the optimization process has converged into two different minima in terms of the hydrogen bonding to the protein, neither of which is substrate-like.
An important feature is that the substituents in the P-and D-pockets have a strong interaction with each other. Each pocket is only precisely definable when the type and location of the substituent in the other pocket is defined. Thus, it is also of value to consider that an inhibitor has to first fold naturally to bring the hydrophobic groups together and then subsequently bind to the double hydrophobic pocket and the rest of the enzyme simultaneously. For MD-805, Matsuzaki et al. (5) indicate that they have single-crystal data of the inhibitor which supports this view, and we have similar experience with analogous compounds. There are no amino acids which differ between human and bovine thrombin and are implicated in inhibitor binding. Thus, all the arguments presented here apply to both species, which is confirmed by the fact that inhibition constants for the two enzymes are very similar.
Understanding the Binding of Other Inhibitors-A number of NAPAP analogs have been described (29) and some of these discussed in Ref. 6. The data for the tighter binding analogs strongly suggest that they bind in the same way as NAPAP. It is clear, for example, that replacement of the piperidine by pyrrolidine ought to be acceptable and that a morpholine would be less favorable because of the hydrophobic nature of the P-pocket, in agreement with the binding data ( Table V) .
A large number of MD-805 analogs have been described (30) (31) (32) (33) . We would argue that all the tighter binding inhibitors (Ki submicromolar) bind in the same way as the reference compound and that the current model provides a most satisfactory explanation of the observed binding data. For example, two aspects of the relative potency of the piperidine stereoisomers of MD-805 were previously difficult to interpret, namely the large differences in affinity of the stereoisomers and the approximately constant ratio of the thrombin and trypsin affinities ( Table VI) . We now propose that the reason for the constant ratio of the affinities is that all four stereoisomers have the same binding energy for the thrombinspecific part of their affinity because this is largely determined by the interaction of the piperidine with the Tyr-Pro-ProTrp loop, which is specific for thrombin and which we now see is able to adapt its structure to different inhibitors. It remains to show that interactions common to both thrombin and trypsin binding are responsible for the marked differences in affinity of the stereoisomers. We have modeled the possible binding of these compounds and come to conclusions which differ from those previously suggested (4, 33). We see no possibility that the piperidine ring rotates to put the carboxylate group facing the protein and are thus left only with the possible conformations which leave the carboxylate near to its observedposition for the (2R,4R) stereoisomer. Our results are shown in Fig. 8 , with the parent structure and the observed positions of the Tyr, Trp, and His of the P-pocket shown for reference (the whole inhibitor was optimized, but the part not shown did not move significantly). In Fig. 8A , we show a first fit of the (2S,4R) compound. We have allowed the carboxylate to adopt the equatorial conformation, as this gives by far the best overall bound structure. The good packing in the P-
TABLE V Inhibitor binding datu for NAPAP and analogs
The K; values of N" substituted para-amidino-phenylalanine amides are taken from Ref. 6 . The para-amidino-phenylalanine is racemic. We find that only the D-configuration binds (with half the K, shown). a-Nas = a-naphthylsulfonyl, P-Nas = P-naphthylsulfonyl. pocket is largely preserved, and we are left with a rather close contact between the carboxylate and the Ca and Cp of G1u2'* (Gln192). This can be relieved somewhat by pushing the carboxylate back toward its observed position in the (2R,4R) compound, at the expense of pushing away the active site histidine. The observed loss of affinity of about two orders of magnitude between the (2R,4R) and (2S,4R) compound is compatible with this model. In Fig. 8B , a first model of the (2R,4S) compound is shown. The axial methyl group collides with the histidine. As the affinity of this stereoisomer is high (Table V) , an alternative structure has to be found. Fig. 8C shows the alternative ring conformation which puts both substituents equatorial. This packs very well with both the protein and the rest of the inhibitor and we propose this as the correct binding mode. Fig. 80 shows the (2S,4S) compound in a starting position which is clearly highly disfavored. Changing the ring conformation as in the (2R,4S) compound above will not help here as the carboxylate would be pushed even further to the left, colliding with the quinoline ring, a sulfone oxygen or the arginine Cp of the inhibitor, or with G1uZo2 (Gln192). There is thus no good binding mode for this stereoisomer, which agrees well with the binding data.
We have shown, then, that it is indeed possible to explain the observed data for both trypsin and thrombin if all possible conformations are considered. We conclude incidentally that the combination of internal packing energy and binding energy is enough in this case to turn the otherwise axial carboxylate into the equatorial conformation. Modeling on the free inhibitor suggests that the more important constraint is that of good internal packing of the inhibitor itself.
As a further point, we note that the compounds described in Refs. 30-32, which were predecessors of MD-805 during its development, do not have quinoline as their aryl moiety, but rather naphthyl or naphthyl derivatives attached at either the a or fi positions. These may be transferred to the model and seem to fit the observed binding data rather well without any rearrangement of the rest of the inhibitor, although in some cases the naphthyl group has to be rotated 180" about the bond to the sulfur relative to the conformation shown in Fig.  4 , in analogy to the NAPAP case already mentioned.
We conclude that modeling based on the observed structures presented above is able to convincingly explain both the relative thrombin affinities and the differences in affinity to thrombin and trypsin of the published analogs of the reference thrombin inhibitors NAPAP and MD-805.
